Your session is about to expire
← Back to Search
Palliative Care for Blood Cancers (PEACE Trial)
N/A
Recruiting
Led By Patrick C Johnson, MD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Diagnosis of a hematologic malignancy
Receiving autologous adoptive cellular therapy (ACT) at MGH with an FDA approved cellular therapy product
Must not have
Already receiving palliative care (PC)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to day 90
Awards & highlights
Summary
This trial is testing if adding special supportive care (PEACE) to regular cancer treatment can improve the quality of life for patients with Lymphoma, Leukemia, or Multiple Myeloma who are receiving adoptive cellular therapy. PEACE aims to help patients feel better by managing pain, symptoms, and emotional stress.
Who is the study for?
This trial is for adults over 18 with blood cancers like Lymphoma, Leukemia, or Multiple Myeloma who are getting a special treatment called ACT at MGH and can complete surveys in English. It's not for those with cognitive issues or uncontrolled mental illness that makes it hard to follow the study rules, or those already in palliative care.
What is being tested?
The study tests if adding a specific type of supportive care (PEACE) to regular cancer treatment helps improve life quality for patients undergoing ACT. Participants will be randomly placed into two groups: one receiving PEACE plus usual care, and the other just usual care.
What are the potential side effects?
Since this trial focuses on palliative care rather than direct medical treatments, side effects aren't the main concern. However, participants may experience various emotional responses to discussions about their illness and future during palliative sessions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with a blood cancer.
Select...
I am getting a cell therapy treatment at MGH that is approved by the FDA.
Select...
I am 18 years old or older.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am currently receiving care to relieve symptoms and improve quality of life.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to day 90
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to day 90
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Percentage of Eligible Participants Enrolled to Palliative Care Intervention (PEACE) (Feasibility)
Secondary study objectives
Acceptability
Anxiety Symptoms
Coping
+6 moreTrial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Palliative Care Intervention (PEACE) GroupExperimental Treatment1 Intervention
Participants will be randomly assigned, and stratified by disease, to the PEACE Group.
* Participants will meet with palliative care (PC) clinician within 1 week of T-cell collection and within 72 hours of hospital admission for ACT.
* Participants will meet with PC clinician at least 2 x weekly during hospitalization.
* PC clinician will follow participants up to one year after randomization (or enrollment for the open pilot) and will meet participant at least 2 x weekly during inpatient hospitalizations.
* Participants will complete follow-up study assessments on pre-determined days per protocol. The assessments will be filled out remotely or via paper.
* Participants will complete exit interviews in the open pilot only.
Group II: Usual Care GroupActive Control1 Intervention
Participants will be randomly assigned, and stratified by disease, to the Usual Care Group and will receive standard care for ACT.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Palliative Care
2011
N/A
~1270
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for leukemia include chemotherapy, targeted therapy, and immunotherapy. Chemotherapy works by using drugs to kill rapidly dividing cancer cells, which can help reduce the number of leukemia cells in the body.
Targeted therapy involves drugs that specifically target and inhibit the function of molecules involved in the growth and survival of cancer cells, thereby limiting the spread of leukemia. Immunotherapy boosts the body's immune system to recognize and destroy leukemia cells.
These treatments are crucial for leukemia patients as they not only aim to control the disease but also improve quality of life by reducing symptoms and prolonging remission periods. Integrating palliative care, such as the PEACE trial, can further enhance patient experiences by addressing physical, emotional, and psychosocial needs, ultimately leading to a more holistic approach to leukemia management.
Care of the patient with hematologic malignancy: a point of view.Acute myeloid leukemia: 2021 update on risk-stratification and management.Analysis of the perceptions and attitudes to participate in radical and palliative clinical trials among Chinese lymphoma and head/neck cancer patients.
Care of the patient with hematologic malignancy: a point of view.Acute myeloid leukemia: 2021 update on risk-stratification and management.Analysis of the perceptions and attitudes to participate in radical and palliative clinical trials among Chinese lymphoma and head/neck cancer patients.
Find a Location
Who is running the clinical trial?
Massachusetts General HospitalLead Sponsor
3,000 Previous Clinical Trials
13,309,409 Total Patients Enrolled
47 Trials studying Leukemia
4,767 Patients Enrolled for Leukemia
Conquer Cancer FoundationOTHER
19 Previous Clinical Trials
3,835 Total Patients Enrolled
Patrick C Johnson, MDPrincipal InvestigatorMassachusetts General Hospital
1 Previous Clinical Trials
80 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have been diagnosed with a blood cancer.I am getting a cell therapy treatment at MGH that is approved by the FDA.I am currently receiving care to relieve symptoms and improve quality of life.I am 18 years old or older.
Research Study Groups:
This trial has the following groups:- Group 1: Palliative Care Intervention (PEACE) Group
- Group 2: Usual Care Group
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger